Our first publication
We sure hope to be bringing thought provoking content, bi-weekly, every time
Greetings, esteemed business enthusiasts, overworked entrepreneurs, and coffee-addicted corporate superheroes!
Here at the "Growth Gazette," we've mastered the art of making business as thought provoking as possible again. We understand that the mundane and monotonous can turn even the most enthusiastic entrepreneur into a spreadsheet-sobbing soul. But fear not! We're here to rescue you from the depths of mundane meetings and banish those pesky buzzwords that haunt your nightmares.
Let's make business, well, bizarrely better together!
The headlines
Worldcoin uses a metal orb to capture people’s biometric data, which they can then use to acquire cryptocurrency (Worldcoin)
WorldCoin, the new crypto project from the creator of ChatGPT planning to scan everyones irises for $60 is exploring the prospect of decentralising it’s proprietary eye scanning service in an effort to gain public trust as it faces regulatory pushback from many countries such as Germany and the UK. The majority of signups are located in newly emerging economies (NEE’s) where most people live and has a third of people live in poverty, though many critics call it an alternative to the KYC system that already exists as well as the legality question in many countries, such as the US.
Recession gloom is over, for now. JPMorgan has came out and backtracked on their earlier prediction of a full-on recession despite interest rates at an all-time high, which are designed to reduce inflation and the economy. The chief economist has upped their predictions for the US economy, 2.5% from 0.5% earlier, for the 3rd quarter. Also, a stream of banks and hedge funds have come out and backtracked from their earlier position such as Goldman Sachs lowered its possibility of a recession to 20% down from 25%.
New pill called “zurzuvae” was given the green light from the US FDA to treat postpartum depression in adults and around 21 million adults have experienced major depressive disorder and affects 1 in 7 women who give birth. Previously, the treatment was administered using an invasive intravenous injection. It’s expected to launch and be commercially available in the 4th quarter of 2023.